 ClearPoint Neuro, Inc. CLPT is pleased to announce that Matthew B. Klein, MD, MS, FACS, has been appointed to ClearPoint Neuros Board of Directors effective immediately. Dr. Klein, Chief Development Officer of PTC Therapeutics, Inc. PTC, is a veteran biotechnology company executive with extensive experience in drug discovery and development, and a board-certified surgeon. Mr. Souza, who resigned from his position as PTCs Chief Operating Officer, as was announced by PTC on March 16, 2020, will remain on ClearPoint Neuros Board as an independent member. 